DALLAS - s4story -- Thousands of patients prescribed Suboxone for opioid addiction treatment are now pursuing legal claims after experiencing severe dental deterioration, including tooth loss, infections, and multiple extractions. The U.S. Food and Drug Administration updated its safety labeling in 2022 to warn of serious dental problems associated with sublingual buprenorphine products — years after the drug entered the market.

Plaintiffs allege that Indivior, the manufacturer of Suboxone, failed to adequately warn patients and prescribers about the dental risks of dissolving the medication under the tongue, where prolonged acid exposure damages tooth enamel. Many patients report having no prior dental problems before starting Suboxone treatment.

More on S For Story

• Indies United is pleased to present our April 2026 book releases
• Century Fasteners Corp. Exhibiting at 2026 MRO Americas Show – April 21-23, 2026 – Booth #2257
• Blue Sparrow Coffee named Best Matcha in Westword's Best of Denver 2026
• Ocean County College Introduces Pathways to Simplify the Student Journey and Strengthen Career Connections
• Kiko Nation Expands to Apple App Store, Achieving Full Mobile Deployment for Livestock Digital Registry Platform

Legal experts note that individuals who took sublingual Suboxone, Subutex, or generic buprenorphine films and subsequently required dental surgery, extractions, or dentures may be eligible to file claims.

For current litigation updates and eligibility information, visit suboxoneinjury.com (http://suboxoneinjury.com/).